Immune checkpoint inhibitors and non-small-cell lung cancer management: 2018 update

被引：11
作者：
Abdel-Rahman, Omar [1 ]
Morris, Don [1 ]
机构：
[1] Univ Calgary, Dept Oncol, Tom Baker Canc Ctr, Calgary, AB, Canada
来源：
IMMUNOTHERAPY | 2019年 / 11卷 / 03期
关键词：
immunotherapy; NSCLC; outcome; prognosis; survival; PD-(L)1 INHIBITORS; NIVOLUMAB; DOCETAXEL; PEMBROLIZUMAB; IMMUNOTHERAPY; TOXICITIES;
D O I：
10.2217/imt-2018-0167
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
[No abstract available]
引用
收藏
页码：149 / 153
页数：5
相关论文
共 32 条
[21]  
Higgs BW, 2018, ANN ONCOL, V29
[22]  
Kim ES, 2018, ANN ONCOL, V29
[23]   Prognostic value of smoking status in non-small-cell lung cancer patients treated with immune checkpoint inhibitors: a meta-analysis [J].
Kim, Jung Han ;
Kim, Hyeong Su ;
Kim, Bum Jun .
ONCOTARGET, 2017, 8 (54) :93149-93155
[24]  
Long GV, 2018, ANN ONCOL
[25]   Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 1%: Open-label, phase 3 KEYNOTE-042 study. [J].
Lopes, Gilberto ;
Wu, Yi-Long ;
Kudaba, Iveta ;
Kowalski, Dariusz ;
Cho, Byoung Chul ;
Castro, Gilberto ;
Srimuninnimit, Vichien ;
Bondarenko, Igor ;
Kubota, Kaoru ;
Lubiniecki, Gregory M. ;
Zhang, Jin ;
Kush, Debra A. ;
Mok, Tony .
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (18)
[26]   Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway [J].
Momtaz, Parisa ;
Postow, Michael A. .
PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2014, 7 :357-365
[27]   Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer [J].
Reck, Martin ;
Rodriguez-Abreu, Delvys ;
Robinson, Andrew G. ;
Hui, Rina ;
Csoszi, Tibor ;
Fulop, Andrea ;
Gottfried, Maya ;
Peled, Nir ;
Tafreshi, Ali ;
Cuffe, Sinead ;
O'Brien, Mary ;
Rao, Suman ;
Hotta, Katsuyuki ;
Leiby, Melanie A. ;
Lubiniecki, Gregory M. ;
Shentu, Yue ;
Rangwala, Reshma ;
Brahmer, Julie R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (19) :1823-1833
[28]   Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial [J].
Rittmeyer, Achim ;
Barlesi, Fabrice ;
Waterkamp, Daniel ;
Park, Keunchil ;
Ciardiello, Fortunato ;
von Pawel, Joachim ;
Gadgeel, Shirish M. ;
Hida, Toyoaki ;
Kowalski, Dariusz M. ;
Dols, Manuel Cobo ;
Cortinovis, Diego L. ;
Leach, Joseph ;
Polikoff, Jonathan ;
Barrios, Carlos ;
Kabbinavar, Fairooz ;
Frontera, Osvaldo Aren ;
De Marinis, Filippo ;
Turna, Hande ;
Lee, Jong-Seok ;
Ballinger, Marcus ;
Kowanetz, Marcin ;
He, Pei ;
Chen, Daniel S. ;
Sandler, Alan ;
Gandara, David R. .
LANCET, 2017, 389 (10066) :255-265
[29]   Cancer immunotherapy: moving beyond current vaccines [J].
Rosenberg, SA ;
Yang, JC ;
Restifo, NP .
NATURE MEDICINE, 2004, 10 (09) :909-915
[30]   iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics [J].
Seymour, Lesley ;
Bogaerts, Jan ;
Perrone, Andrea ;
Ford, Robert ;
Schwartz, Lawrence H. ;
Mandrekar, Sumithra ;
Lin, Nancy U. ;
Litiere, Saskia ;
Dancey, Janet ;
Chen, Alice ;
Hodi, F. Stephen ;
Therasse, Patrick ;
Hoekstra, Otto S. ;
Shankar, Lalitha K. ;
Wolchok, Jedd D. ;
Ballinger, Marcus ;
Caramella, Caroline ;
de Vries, Elisabeth G. E. .
LANCET ONCOLOGY, 2017, 18 (03) :E143-E152
1234